Internal Medicine, Hematology & Oncology · Chester, PA
NPI
1992964696
Since 2008
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
3
Medicare group memberships
Hospitals
3
Hospital affiliations
1 Medical Center Blvd, Suite 341
Chester, PA, 19013
Phone (610) 619-7420
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
149,952 services
Medicare patients, 2024
554
Average age 75
Drug cost, 2024
$5.4M
1,797 prescriptions
Company payments, 2025
$1,781
From 43 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Mylene S Go was code J1439 (injection, ferric carboxymaltose, 1 mg), 63,750 times for 53 patients. In total Mylene S Go billed 149,952 services in 97 codes, and Medicare paid $2.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2014-09-30.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J1439 Injection, ferric carboxymaltose, 1 mg | Office | 63,750 | 53 | $0.87 | $56K |
| J9271 Injection, pembrolizumab, 1 mg | Office | 13,000 | 17 | $44.81 | $583K |
| J1449 Injection, eflapegrastim-xnst, 0.1 mg | Office | 6,072 | 22 | $20.59 | $125K |
| J9267 Injection, paclitaxel, 1 mg | Office | 3,923 | 13 | $0.08 | $318 |
| J0897 Injection, denosumab, 1 mg | Office | 3,000 | 25 | $20.45 | $61K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 2,860 | 19 | $5.62 | $16K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2,140 | 21 | $6.38 | $14K |
| J1453 Injection, fosaprepitant, 1 mg | Office | 2,100 | 11 | $0.11 | $241 |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,313 | 53 | $0.09 | $118 |
| 85025 Blood Count | Office | 984 | 356 | $7.59 | $7,465 |
| J2405 Injection, ondansetron hydrochloride, per 1 mg | Office | 880 | 19 | $0.07 | $64.71 |
| 99214 Office E&M - Established | Office | 779 | 347 | $107.50 | $84K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 610 | 30 | $0.68 | $413 |
| 96375 Injection Administration | Office | 328 | 61 | $13.89 | $4,555 |
| 96372 Injection Administration | Office | 320 | 107 | $12.48 | $3,994 |
By year: 2022 $1.8M for 132,282 services; 2023 $1.7M for 133,556 services; 2024 $2.0M for 149,952 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 984 | 356 | $7.59 | $7,465 |
| 80053 Clinical Chemistry | 50 | 25 | $10.35 | $518 |
Medicare prescription drug claims, 2024
In 2024, the drug Mylene S Go prescribed most often to Medicare patients was Eliquis (Apixaban), with 197 prescriptions and refills. In total Mylene S Go wrote 1,797 Medicare prescriptions that cost $5.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 197 | 221 | 35 | $125K |
| Anastrozole Generic | 173 | 386 | 53 | $4,452 |
| Letrozole Generic | 79 | 206 | 26 | $1,937 |
| Procrit Epoetin Alfa | 49 | 56 | Under 11 | $68K |
| Keytruda Pembrolizumab | 49 | 51 | Under 11 | $607K |
| Oxycodone Hcl Generic | 46 | 46 | 20 | $722 |
| Xarelto Rivaroxaban | 45 | 79 | 12 | $43K |
| Darzalex Faspro Daratumumab-Hyaluronidase-Fihj | 43 | 43 | Under 11 | $733K |
| Hydroxyurea Generic | 42 | 74 | 11 | $651 |
| Dexamethasone Generic | 36 | 38 | 13 | $282 |
| Levothyroxine Sodium Generic | 32 | 42 | Under 11 | $157 |
| Ondansetron Odt Ondansetron | 30 | 30 | 20 | $463 |
| Gabapentin Generic | 29 | 33 | 14 | $265 |
| Revlimid Lenalidomide | 27 | 27 | Under 11 | $473K |
| Prednisone Generic | 26 | 40 | 11 | $107 |
Brand drugs: 781 claims; generic drugs: 1,016 claims; opioid claims: 75.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Mylene S Go $1,781 ($1,781 in general payments such as food, travel and fees) from 43 companies. The largest payer was Novartis Pharmaceuticals Corporation with $183.
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation NVS | 9 | $183 |
| Daiichi Sankyo Inc. 4568.T | 5 | $119 |
| Merck Sharp & Dohme LLC MRK | 5 | $101 |
| GlaxoSmithKline, LLC. GSK | 5 | $96.29 |
| AstraZeneca Pharmaceuticals LP AZN | 5 | $85.5 |
| Pfizer Inc. PFE | 4 | $70.44 |
| Abbvie Inc. ABBV | 4 | $62.62 |
| Invivyd Inc IVVD | 2 | $61.36 |
| Pharmacosmos Therapeutics Inc. | 3 | $55.64 |
| BeOne Medicines USA, Inc. ONC | 3 | $51.43 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.